Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.

What symbol and exchange does Azora Therapeutics shares trade?

Last close: $3.74 (November 12, 2026)
52-week range: $3.02 to $4.97
Market value: $9.8 million
Next earnings: November 12, 2026, after the market closes (confirmed)

Azora Therapeutics trades on the NASDAQ stock market under the symbol AZR.

What is Azora Therapeutics stock price doing today?

As of November 12, 2026, AZR stock price climbed to $3.74 with 50,804 million shares trading.

How much is Azora Therapeutics worth?

AZR has a market cap of $9.82 million. This is considered a Sub-Micro Cap stock.

What are the support and resistance levels for Azora Therapeutics (AZR)?

AZR support price is $2.98 and resistance is $4.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZR shares will trade within this expected range on the day.